These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 290759)

  • 21. [Serotoninergic conception of myoclonic syndromes. (Review)].
    Levin SL
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1979; 79(6):797-803. PubMed ID: 224629
    [No Abstract]   [Full Text] [Related]  

  • 22. Reticular reflex myoclonus: a physiological type of human post-hypoxic myoclonus.
    Hallett M; Chadwick D; Adam J; Marsden CD
    J Neurol Neurosurg Psychiatry; 1977 Mar; 40(3):253-64. PubMed ID: 301926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathological findings in a case of hypoxic myoclonus treated with 5-hydroxytryptophan and a decarboxylase inhibitor.
    De Léan J; Richardson JC; Rewcastle NB
    Adv Neurol; 1986; 43():215-23. PubMed ID: 2418647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluoxetine in the treatment of intention myoclonus.
    Van Woert MH; Magnussen I; Rosenbaum D; Chung E
    Clin Neuropharmacol; 1983 Mar; 6(1):49-54. PubMed ID: 6189599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Animal model of posthypoxic myoclonus: effects of serotonergic antagonists.
    Pappert EJ; Goetz CG; Vu TQ; Ling ZD; Leurgans S; Raman R; Carvey PM
    Neurology; 1999 Jan; 52(1):16-21. PubMed ID: 9921842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of myoclonic syndromes with paroxetine alone or combined with 5-HTP.
    Magnussen I; Mondrup K; Engbaek F; Lademann A; Olivarius BD
    Acta Neurol Scand; 1982 Aug; 66(2):276-82. PubMed ID: 6215817
    [No Abstract]   [Full Text] [Related]  

  • 27. Postanoxic myoclonus. Treatment of a case with 5-hydroxytryptophane and a decarboxylase inhibitor.
    Beretta E; Regli F; de Crousaz G; Steck AJ
    J Neurol; 1981; 225(1):57-62. PubMed ID: 6164757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam.
    Chadwick D; Hallett M; Harris R; Jenner P; Reynolds EH; Marsden CD
    Brain; 1977 Sep; 100(3):455-87. PubMed ID: 412560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of postanoxic intention myoclonus with valproic acid.
    Bruni J; Willmore LJ; Wilder BJ
    Can J Neurol Sci; 1979 Feb; 6(1):39-42. PubMed ID: 122539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacologic analysis of a new case of postanoxic intention and action myoclonus].
    Lhermitte F; Marteau R; Degos CF
    Rev Neurol (Paris); 1972 Feb; 126(2):107-14. PubMed ID: 4654779
    [No Abstract]   [Full Text] [Related]  

  • 31. Antimyoclonic properties of S2 serotonin receptor antagonists in the rat.
    Pranzatelli MR; Snodgrass SR
    Neuropharmacology; 1986 Jan; 25(1):5-12. PubMed ID: 2936977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Letter: Treatment of post-anoxic intention myoclonus.
    Van Woert MH; Sethy VH
    Lancet; 1974 Jun; 1(7869):1285. PubMed ID: 4134164
    [No Abstract]   [Full Text] [Related]  

  • 33. Action myoclonus following acute cerebral anoxia.
    DeLisa JA; Stolov WC; Troupin AS
    Arch Phys Med Rehabil; 1979 Jan; 60(1):32-6. PubMed ID: 420569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Action myoclonus, Ramsay Hunt syndrome, and other cerebellar myoclonic syndromes.
    Lance JW
    Adv Neurol; 1986; 43():33-55. PubMed ID: 3080851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations.
    Thal LJ; Sharpless NS; Wolfson L; Katzman R
    Ann Neurol; 1980 Jun; 7(6):570-6. PubMed ID: 6969054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The proposed role of neurotransmitter receptors in the pathophysiology of human myoclonic disorders.
    Pranzatelli MR
    Med Hypotheses; 1989 Sep; 30(1):55-60. PubMed ID: 2571916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical challenge of posthypoxic myoclonus.
    Frucht SJ
    Adv Neurol; 2002; 89():85-8. PubMed ID: 11968475
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical and metabolic observations on the treatment of myoclonus with L-5-HTP and carbidopa.
    Thal L; Sharpless N; Wolfson L; Engel J; Katzman R
    Trans Am Neurol Assoc; 1976; 101():48-52. PubMed ID: 1088459
    [No Abstract]   [Full Text] [Related]  

  • 39. Serotonin models of myoclonus in the guinea pig and rat.
    Wolfson LI; Thal LJ; Brown LL
    Adv Neurol; 1986; 43():519-27. PubMed ID: 3484858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Action myoclonus and serotoninergic activity.
    De Lèan J
    N Engl J Med; 1977 Jun; 296(24):1414-5. PubMed ID: 859554
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.